Den europeiske union - norsk - EMA (European Medicines Agency)

pfizer europe ma eeig - temsirolimus - carcinoma, renal cell; lymphoma, mantle-cell - antineoplastiske midler - nyre-celle carcinomatorisel er angitt for det første-linje behandling av voksne pasienter med avansert nyre-cell carcinoma (rcc) som har minst tre av seks prognostiske risikofaktorer. kappe-celle lymphomatorisel er indisert for behandling av voksne pasienter med tilbakefall og / eller ildfast kappe-celle lymfom (mcl).

Den europeiske union - norsk - EMA (European Medicines Agency)

pfizer europe ma eeig - fesoterodinfumarat - urinblære, overaktiv - urologika - behandling av symptomene (økt urinfrekvens og / eller haster og / eller hasterinkontinens) som kan oppstå hos pasienter med overaktiv-blære syndrom.

Den europeiske union - norsk - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - leddgikt, reumatoid - immunsuppressive - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 og 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibakterielle midler for systemisk bruk, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.

Den europeiske union - norsk - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - antibakterielle midler for systemisk bruk, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.

Den europeiske union - norsk - EMA (European Medicines Agency)

pfizer europe ma eeig - zoledronsyre monohydrat - hyperkalsemi - legemidler til behandling av bein sykdommer - 4 mg / 5 ml og 4 mg / 100 ml:forebygging av skjelett-relaterte hendelser (patologiske frakturer, spinal-komprimering, stråling eller kirurgi til bein, eller tumor-indusert hyperkalsemi) hos voksne pasienter med avansert malignitet involverer bein. behandling av voksne pasienter med tumor-indusert hyperkalsemi (tih). 5 mg / 100 ml:behandling av osteoporose:i post-menopausal kvinner;menn;økt risiko for brudd, inkludert de med en ny lav-traumer hoftebrudd. behandling av osteoporose forbundet med langvarig systemisk glukokortikoid terapi:i post-menopausal kvinner;menn;økt risiko for brudd. behandling av pagets sykdom i beinet i voksne.

Den europeiske union - norsk - EMA (European Medicines Agency)

pfizer europe ma eeig - inotuzumab ozogamicin - forløpercellelymfoblastisk leukemi-lymfom - antineoplastiske midler - besponsa er indisert som monoterapi for behandling av voksne med tilbakevendende eller refraktær cd22-positiv b-celleprecursor akutt lymfoblastisk leukemi (all). voksenpatienter med philadelphia-kromosom-positiv (ph +) tilbakefallende eller ildfast b-celleforløper alle skal ha mislyktes behandling med minst 1 tyrosinkinasehemmer (tki).

Norge - norsk - Statens legemiddelverk

pfizer as - doksorubicinhydroklorid - pulver til injeksjonsvæske, oppløsning - 10 mg

Norge - norsk - Statens legemiddelverk

pfizer as - spironolakton - tablett, filmdrasjert - 50 mg

Norge - norsk - Statens legemiddelverk

pfizer as - donepezilhydroklorid - tablett, filmdrasjert - 10 mg